ClinicalTrials.govpublic full text
A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
advanced solid tumor cancer, metastatic solid tumor, ze94-0605, selective cdk2 inhibitor, ccne1 amplification, cyclin e1, first-in-human, dose escalation, dose optimization, recommended phase 2 dose, project optimus, brain-penetrant cdk2 inhibitor
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 1047833
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.